BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors

European Journal of Clinical Pharmacology

Volumn 67, Issue 11, 2011, Pages 1147-1157

  Chianella, Caterina ^a   Gragnaniello, Daniela ^b   Maisano Delser, Pierpaolo ^a,c   Visentini, Maria Francesca ^a,d   Sette, Elisabetta ^b   Tola, Maria Rosaria ^b   Barbujani, Guido ^a   Fuselli, Silvia ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b Azienda Ospedale Università S Anna   (Italy)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d NGB Genetics Srl   (Italy)

Author keywords

Alzheimer; BCHE; cholinesterase inhibitors; CYP2D6; pharmacogenetics

Indexed keywords

CHOLINESTERASE INHIBITOR; CITALOPRAM; DONEPEZIL; ESCITALOPRAM; GALANTAMINE; PAROXETINE; RIVASTIGMINE;

ABDOMINAL PAIN; ADULT; AGED; AGITATION; ALZHEIMER DISEASE; APOLIPOPROTEIN E GENE; ARTICLE; BUTYRYLCHOLINESTERASE GENE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CYP2D6 GENE; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FALLING; FEMALE; GENE; GENE LOCUS; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HALLUCINATION; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MARKER GENE; NAUSEA; NEUROPATHOLOGY; PATIENT ASSESSMENT; PHARMACOGENETICS; PHYSICAL ACTIVITY; PREDICTION; PRIORITY JOURNAL; RASH; RELIABILITY; SIDE EFFECT; SWEATING; TREATMENT DURATION; VERTIGO;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; COGNITION; CYTOCHROME P-450 CYP2D6; FEMALE; GALANTAMINE; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; GENOTYPE; HUMANS; INDANS; MALE; MIDDLE AGED; PHENYLCARBAMATES; PIPERIDINES; TREATMENT OUTCOME;

EID: 80054742063     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1064-x     Document Type: Article

References (45)

1. L Jonsson A Wimo 2009 The cost of dementia in Europe: a review of the evidence, and methodological considerations Pharmacoeconomics 27 391 403 19586077 10.2165/00019053-200927050-00004
2. Dementia in Europe: Yearbook 2006 (2006). Alzheimer Europe. Available at: http://www.alzheimer-europe.org
3. G Waldemar B Dubois M Emre J Georges IG McKeith M Rossor P Scheltens P Tariska B Winblad 2007 Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline Eur J Neurol 14 e1 e26 17222085 10.1111/j.1468-1331.2006.01605.x 1:STN:280:DC%2BD2s%2FisFSqsA%3D%3D (Pubitemid 46088015)
4. PV Rabins D Blacker BW Rovner T Rummans LS Schneider PN Tariot DM Blass JS McIntyre SC Charles DJ Anzia IA Cook MT Finnerty BR Johnson JE Nininger B Schneidman P Summergrad SM Woods J Berger CD Cross HA Brandt PM Margolis JP Shemo BJ Blinder DL Duncan MA Barnovitz AJ Carino ZZ Freyberg SH Gray T Tonnu R Kunkle AB Albert TJ Craig DA Regier LJ Fochtmann 2007 American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition Am J Psychiatry 164 5 56 18340692
5. CG Ballard 2002 Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition Eur Neurol 47 64 70 11803198 10.1159/000047952 1:CAS:528:DC%2BD38XmtFGhsA%3D%3D
6. MW Jann KL Shirley GW Small 2002 Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors Clin Pharmacokinet 41 719 739 12162759 10.2165/00003088-200241100-00003 1:CAS:528:DC%2BD38XntFyrurk%3D (Pubitemid 34948194)
7. R Cacabelos R Llovo C Fraile L Fernandez-Novoa 2007 Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics Curr Alzheimer Res 4 479 500 17908053 10.2174/156720507781788846 1:CAS:528:DC%2BD2sXhtlSitLzO (Pubitemid 47416643)
8. F Varsaldi G Miglio MG Scordo ML Dahl LM Villa A Biolcati G Lombardi 2006 Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients Eur J Clin Pharmacol 62 721 726 16845507 10.1007/s00228-006-0168-1 1:CAS:528: DC%2BD28XotlCht7w%3D (Pubitemid 44289502)
9. R Scacchi G Gambina G Moretto RM Corbo 2009 Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine Am J Med Genet B Neuropsychiatr Genet 150B 502 507 18780301 10.1002/ajmg.b.30846 1:CAS:528:DC%2BD1MXnvVWks74%3D
10. A Pilotto M Franceschi G D'Onofrio A Bizzarro F Mangialasche L Cascavilla F Paris MG Matera A Pilotto A Daniele P Mecocci C Masullo B Dallapiccola D Seripa 2009 Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease Neurology 73 761 767 19738170 10.1212/WNL.0b013e3181b6bbe3 1:CAS:528:DC%2BD1MXhtVKrsbjI
11. Seripa D, Bizzarro A, Pilotto A, D'Onofrio G, Vecchione G, Gallo AP, Cascavilla L, Paris F, Grandone E, Mecocci P, Santini SA, Masullo C (2011) Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease. Pharmacogenet Genomics 21(4):225-320
12. G McKhann D Drachman M Folstein R Katzman D Price EM Stadlan 1984 Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 939 944 6610841 1:STN:280:DyaL2c3ks1altQ%3D%3D (Pubitemid 14076461)
13. MF Folstein SE Folstein PR McHugh 1975 Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 189 198 1202204 10.1016/0022-3956(75)90026-6 1:STN:280:DyaE28%2FntFKjtw%3D%3D
14. E Magni G Binetti A Bianchetti R Rozzini M Trabucchi 1996 Mini-mental State Examination: a normative study in Italian elderly population Eur J Neurol 3 1 5 10.1111/j.1468-1331.1996.tb00423.x
15. Flockhart D (2007) Drug interactions: cytochrome P450 drug interaction table. Available at: http://medicine.iupui.edu/clinpharm/ddis/table.asp. Indiana University School of Medicine, version 5.0 released on 12 Jan 2009
16. S Katz 1983 Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living J Am Geriatr Soc 31 721 727 6418786 1:STN:280:DyaL2c%2FovVKrug%3D%3D (Pubitemid 14209563)
17. MP Lawton EM Brody 1969 Assessment of older people: self-maintaining and instrumental activities of daily living Gerontologist 9 179 186 5349366 10.1093/geront/9.3-Part-1.179 1:STN:280:DyaE3c%2FivV2kug%3D%3D
18. Schipper HM (2011) Apolipoprotein E: implications for AD neurobiology, epidemiology and risk assessment. Neurobiol Aging 32(5):778-790
19. J Sistonen S Fuselli A Levo A Sajantila 2005 CYP2D6 genotyping by a multiplex primer extension reaction Clin Chem 51 1291 1295 15905314 10.1373/clinchem.2004.046466 1:CAS:528:DC%2BD2MXlsleqsbs%3D (Pubitemid 43079419)
20. A Levo A Koski I Ojanpera E Vuori A Sajantila 2003 Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood Forensic Sci Int 135 9 15 12893130 10.1016/S0379-0738(03)00159-2 1:CAS:528:DC%2BD3sXlvVCqsLY%3D (Pubitemid 36957845)
21. W Koch A Ehrenhaft K Griesser A Pfeufer J Muller A Schomig A Kastrati 2002 TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E Clin Chem Lab Med 40 1123 1131 12521230 10.1515/CCLM.2002.197 1:CAS:528:DC%2BD3sXhtV2murs%3D (Pubitemid 36032659)
22. L Excoffier G Laval S Schneider 2005 Arlequin ver. 3.0: An integrated software package for population genetics data analysis Evol Bioinform Online 1 47 50 1:CAS:528:DC%2BD28XjsFSltg%3D%3D
23. A Gaedigk SD Simon RE Pearce LD Bradford MJ Kennedy JS Leeder 2008 The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype Clin Pharmacol Ther 83 234 242 17971818 10.1038/sj.clpt.6100406 1:STN:280:DC%2BD1c%2FkslCqug%3D%3D
24. CF Bartels FS Jensen O Lockridge AF van der Spek HM Rubinstein T Lubrano BN La Du 1992 DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites Am J Hum Genet 50 1086 1103 1570838 1:CAS:528:DyaK38XkvVCntbw%3D
25. E Podoly DE Shalev S Shenhar-Tsarfaty ER Bennett E Ben Assayag H Wilgus O Livnah H Soreq 2009 The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology J Biol Chem 284 17170 17179 19383604 10.1074/jbc.M109.004952 1:CAS:528:DC%2BD1MXntFCjtLg%3D
26. A Tasker CG Ballard C Joachim DR Warden EJ Okello RH Perry N Khan AD Smith DJ Lehmann EK Perry 2008 Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients Neurosci Lett 442 297 299 18640242 10.1016/j.neulet.2008.07.023 1:CAS:528:DC%2BD1cXps1Ggu7Y%3D
27. StatSoft (2005) STATISTICA ver. 7.1. Available at: StatSoft.Italia-srl
28. E Aguglia ML Onor M Saina E Maso 2004 An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting Curr Med Res Opin 20 1747 1752 15537474 10.1185/030079904X6273 1:CAS:528: DC%2BD2MXls1Ggtg%3D%3D (Pubitemid 39611933)
29. Patterson CE, Todd SA, Passmore AP (2010) Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease. Pharmacogenomics J. doi: 10.1038/tpj.2010.61
30. R Bullock H Bergman J Touchon G Gambina Y He J Nagel R Lane 2006 Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease Curr Med Res Opin 22 483 494 16574032 10.1185/030079906X89685 1:CAS:528:DC%2BD28XjvV2ht7o%3D
31. S Fuselli I Dupanloup E Frigato F Cruciani R Scozzari P Moral J Sistonen A Sajantila G Barbujani 2004 Molecular diversity at the CYP2D6 locus in the Mediterranean region Eur J Hum Genet 12 916 924 15340360 10.1038/sj.ejhg.5201243 1:CAS:528:DC%2BD2cXosFyltLw%3D (Pubitemid 39462125)
32. J Sistonen S Fuselli JU Palo N Chauhan H Padh A Sajantila 2009 Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales Pharmacogenet Genomics 19 170 179 19151603 10.1097/FPC.0b013e32831ebb30 1:CAS:528:DC%2BD1MXmvVartg%3D%3D
33. KK O'Brien BK Saxby CG Ballard J Grace F Harrington GA Ford JT O'Brien AG Swan AF Fairbairn K Wesnes T del Ser JA Edwardson CM Morris IG McKeith 2003 Regulation of attention and response to therapy in dementia by butyrylcholinesterase Pharmacogenetics 13 231 239 12668920 10.1097/00008571- 200304000-00008 (Pubitemid 36543396)
34. R Blesa R Bullock Y He H Bergman G Gambina J Meyer G Rapatz J Nagel R Lane 2006 Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease Pharmacogenet Genomics 16 771 774 17047484 10.1097/01.fpc.0000220573.05714.ac 1:CAS:528:DC%2BD28XhtVynsLjF (Pubitemid 44632290)
35. UM Zanger S Raimundo M Eichelbaum 2004 Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry Naunyn-Schmiedebergs Arch Pharmacol 369 23 37 14618296 10.1007/s00210-003-0832-2 1:CAS:528: DC%2BD2cXitF2hsQ%3D%3D (Pubitemid 38161221)
36. A Gaedigk DL Ryder LD Bradford JS Leeder 2003 CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584 G promoter polymorphism Clin Chem 49 1008 1011 12766015 10.1373/49.6.1008 1:CAS:528:DC%2BD3sXkt1Omt70%3D (Pubitemid 36623498)
37. S Raimundo C Toscano K Klein J Fischer EU Griese M Eichelbaum M Schwab UM Zanger 2004 A novel intronic mutation, 2988G > A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects Clin Pharmacol Ther 76 128 138 15289790 10.1016/j.clpt.2004.04.009 1:CAS:528:DC%2BD2cXmt1OgurY%3D (Pubitemid 39013403)
38. C Rodriguez-Antona D Gurwitz J de Leon A Llerena J Kirchheiner EG de Mesa D Ibarreta 2009 CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies Pharmacogenomics 10 685 699 10.2217/pgs.09.15 19374522 10.2217/pgs.09.15 1:CAS:528: DC%2BD1MXkslGntbo%3D
39. ME Risner AM Saunders JF Altman GC Ormandy S Craft IM Foley ME Zvartau-Hind DA Hosford AD Roses 2006 Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease Pharmacogenomics J 6 246 254 16446752 1:CAS:528:DC%2BD28Xnt1agu7k%3D (Pubitemid 44137951)
40. B Borroni F Colciaghi L Pastorino S Archetti P Corsini F Cattabeni M Di Luca A Padovani 2002 ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model Eur Neuropsychopharmacol 12 195 200 12007670 10.1016/S0924-977X(02)00013-5 1:CAS:528:DC%2BD38Xjtl2nur0%3D (Pubitemid 34464109)
41. J Poirier MC Delisle R Quirion I Aubert M Farlow D Lahiri S Hui P Bertrand J Nalbantoglu BM Gilfix S Gauthier 1995 Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease Proc Natl Acad Sci USA 92 12260 12264 8618881 10.1073/pnas.92.26.12260 1:CAS:528:DyaK28Xhtl2guw%3D%3D (Pubitemid 26014050)
42. MR Farlow DK Lahiri J Poirier J Davignon L Schneider SL Hui 1998 Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease Neurology 50 669 677 9521254 1:CAS:528:DyaK1cXitlymsLo%3D
43. J Aerssens P Raeymaekers S Lilienfeld H Geerts F Konings W Parys 2001 APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease Dement Geriatr Cogn Disord 12 69 77 11173877 10.1159/000051238 1:CAS:528:DC%2BD3MXitFOju7Y%3D (Pubitemid 32149710)
44. AS Rigaud L Traykov F Latour R Couderc F Moulin F Forette 2002 Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease Pharmacogenetics 12 415 420 12142731 10.1097/00008571-200207000-00009 1:CAS:528:DC%2BD38Xmslejtrg%3D (Pubitemid 34816421)
45. MR Farlow 2003 Clinical pharmacokinetics of galantamine Clin Pharmacokinet 42 1383 1392 14674789 10.2165/00003088-200342150-00005 1:CAS:528:DC%2BD2cXptF2lug%3D%3D (Pubitemid 38045842)